Active, not recruitingPhase 3NCT04624204
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Studying Autosomal dominant multiple pterygium syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical Director, MDMerck Sharp & Dohme LLC
- Intervention
- Pembrolizumab 200 mg(biological)
- Enrollment
- 672 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Ironwood Cancer & Research Centers ( Site 0007), Chandler, Arizona, United States
- Loma Linda University Cancer Center ( Site 0011), Loma Linda, California, United States
- Georgetown University ( Site 0017), Washington D.C., District of Columbia, United States
- Moffitt Cancer Center ( Site 0137), Tampa, Florida, United States
- University of Chicago Medical Center ( Site 0136), Chicago, Illinois, United States
- Fort Wayne Medical Oncology and Hematology ( Site 0034), Fort Wayne, Indiana, United States
- University of Kentucky Chandler Medical Center ( Site 0138), Lexington, Kentucky, United States
- Overton Brooks VAMC ( Site 0041), Shreveport, Louisiana, United States
- Harry & Jeanette Weinberg Cancer Institute ( Site 0045), Baltimore, Maryland, United States
- VA Ann Arbor Healthcare System ( Site 0050), Ann Arbor, Michigan, United States
- St. Vincent Healthcare Frontier Cancer Center ( Site 0056), Billings, Montana, United States
- Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0061), Omaha, Nebraska, United States
- Memorial Sloan Kettering - Basking Ridge ( Site 0133), Basking Ridge, New Jersey, United States
- John Theurer Cancer Center ( Site 0064), Hackensack, New Jersey, United States
- Memorial Sloan Kettering - Monmouth ( Site 0135), Middletown, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04624204 on ClinicalTrials.govOther trials for Autosomal dominant multiple pterygium syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06941012Validation of α-synuclein Modifications in Parkinson's dIsoRder EvolutionCasa di Cura IGEA
- RECRUITINGNCT06949670Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTianjin Medical University
- RECRUITINGPHASE3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT05281003Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Fudan University
- ACTIVE NOT RECRUITINGPHASE1NCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Merck Sharp & Dohme LLC
- RECRUITINGNCT07533799The Swedish BioFINDER Sleep StudySkane University Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Merck Sharp & Dohme LLC
See all trials for Autosomal dominant multiple pterygium syndrome →